Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Dermira craters as acne drug fails late-stage test

Dermira craters as acne drug fails late-stage test. The US biotech lost two-thirds of its share value after the news broke. ... s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially

Latest news

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AZ gets EMA green light for severe asthma drug Fasenra. The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero. ... The new drug has been given a green light by the EMA as an add-on maintenance treatment for severe

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    AZ prices severe asthma drug Fasenra below competition. The discounted drug will cost $38, 000 in the first year. ... The US regulator has approved the drug as an add-on treatment for severe eosinophilic asthma in patients over 12.

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... In trials, benralizumab achieved up to 51% reduction in the annual asthma exacerbations rate (AERR) versus placebo,

  • GSK preps COPD filing for asthma pioneer Nucala GSK preps COPD filing for asthma pioneer Nucala

    GlaxoSmithKline is moving swiftly ahead with plans to file interleukin-5 inhibitor Nucala in chronic obstructive pulmonary disease (COPD), in hope of extending use of the drug beyond severe asthma. ... high-risk form of the disease, despite reporting

  • GSK starts trial of Nucala to seek alternate indications GSK starts trial of Nucala to seek alternate indications

    GSK starts trial of Nucala to seek alternate indications. Asthma therapy drug to be used to target severe nasal polyposis. ... It is estimated that 20-40% of people with nasal polyps also have asthma.

More from news
Approximately 2 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • US health reforms US health reforms

    In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    Enterprise Therapeutics appoints CEO. Dr John Ford will lead the UK drug discovery company. ... He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.

  • Former RBS head takes the reins as GSK chair Former RBS head takes the reins as GSK chair

    the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Quick links

Infographics

Multimedia